Review



non hdl cholesterol  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Thermo Fisher non hdl cholesterol
    Summary of included studies.
    Non Hdl Cholesterol, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/Cholesterol/pmc12914095-0-100-131
    Average 97 stars, based on 1 article reviews
    non hdl cholesterol - by Bioz Stars, 2026-10
    97/100 stars

    Images

    1) Product Images from "Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis"

    Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis

    Journal: International Journal of Cardiology. Cardiovascular Risk and Prevention

    doi: 10.1016/j.ijcrp.2026.200590


    Figure Legend Snippet: Summary of included studies.

    Techniques Used: Control, Biomarker Discovery, Clinical Proteomics, Activation Assay

    Related Articles

    Biomarker Discovery:

    Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis
    Article Snippet: .. Clavijoa, 2023 , RCT, Double-blind , USA , 6 months , Evolocumab 420 mg SC q4w , placebo , 35 , 35 , 70 , Patients aged 40–85 years with a diagnosis of atherosclerotic cardiovascular disease and PAD (Rutherford class I-VI), confirmed by an ankle-brachial index (ABI) ≤0.9 at rest or ≤0.8 after exercise, angiography, duplex ultrasound, or a history of lower extremity surgical or endovascular revascularization. Patients had to be at least one month from their most recent intervention, stable on maximal tolerated lipid-lowering therapy for at least four weeks, and have a fasting LDL cholesterol ≥55 mg/dL or non-HDL cholesterol ≥80 mg/dL. , MWT at 6 months , After six months, Evolocumab significantly improved MWT, FMD, Carotid IMT, and plasma MRP-14 levels. In contrast, changes in pain-free walking time, ABI, TBI, transcutaneous oxygen pressure, oxLDL, and sCD36 were not statistically significant.. .. Sato, 2020 , PO, Single center , Japan , 18 ± 11 months , Evolocumab, 140 mg SC q2w or 420 mg, SC q4w , placebo , 14 , 16 , 30 , Patients with CLTI were eligible if they had either ischemic foot rest pain with ABI <0.4, ankle pressure <50 mmHg, toe pressure <30 mmHg, or SPP <30 mmHg, or if they presented with a foot ulcer or gangrene accompanied by significant PAD. Those considered for evolocumab had to be on high-intensity statin therapy, have at least one major cardiovascular risk factor (such as CAD, stroke, CKD, or diabetes), and an LDL-C level ≥70 mg/dL , 12-month freedom from major amputation , After 12 months, evolocumab significantly improved amputation-free survival, wound-free limb salvage, and lipid parameters (LDL-C, non-HDL-C, MDA-LDL). Conversely, changes in freedom from major amputation, overall survival, and ABI were not statistically significant..

    Clinical Proteomics:

    Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis
    Article Snippet: .. Clavijoa, 2023 , RCT, Double-blind , USA , 6 months , Evolocumab 420 mg SC q4w , placebo , 35 , 35 , 70 , Patients aged 40–85 years with a diagnosis of atherosclerotic cardiovascular disease and PAD (Rutherford class I-VI), confirmed by an ankle-brachial index (ABI) ≤0.9 at rest or ≤0.8 after exercise, angiography, duplex ultrasound, or a history of lower extremity surgical or endovascular revascularization. Patients had to be at least one month from their most recent intervention, stable on maximal tolerated lipid-lowering therapy for at least four weeks, and have a fasting LDL cholesterol ≥55 mg/dL or non-HDL cholesterol ≥80 mg/dL. , MWT at 6 months , After six months, Evolocumab significantly improved MWT, FMD, Carotid IMT, and plasma MRP-14 levels. In contrast, changes in pain-free walking time, ABI, TBI, transcutaneous oxygen pressure, oxLDL, and sCD36 were not statistically significant.. .. Sato, 2020 , PO, Single center , Japan , 18 ± 11 months , Evolocumab, 140 mg SC q2w or 420 mg, SC q4w , placebo , 14 , 16 , 30 , Patients with CLTI were eligible if they had either ischemic foot rest pain with ABI <0.4, ankle pressure <50 mmHg, toe pressure <30 mmHg, or SPP <30 mmHg, or if they presented with a foot ulcer or gangrene accompanied by significant PAD. Those considered for evolocumab had to be on high-intensity statin therapy, have at least one major cardiovascular risk factor (such as CAD, stroke, CKD, or diabetes), and an LDL-C level ≥70 mg/dL , 12-month freedom from major amputation , After 12 months, evolocumab significantly improved amputation-free survival, wound-free limb salvage, and lipid parameters (LDL-C, non-HDL-C, MDA-LDL). Conversely, changes in freedom from major amputation, overall survival, and ABI were not statistically significant..

    Activity Assay:

    Article Title: Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population
    Article Snippet: .. Association Between Risk Factors and High Ankle Brachial Index in Patients With An Ankle Brachial Index ≥0.9 Determinant (Predictor) of the Model OR (95% CI) for Having High ABI P Value Age (per 10 y) 1.26 (1.15–1.39) <0.001 Sex (male) 3.00 (2.20–4.09) <0.001 Diabetes mellitus (type 1 or 2) 1.54 (1.21–1.98) <0.001 BMI (per 1 kg/m2) 1.04 (1.01–1.06) 0.004 Non-HDL cholesterol (per 1 mmol/L) 0.89 (0.82–0.98) 0.014 History of hypertension (treated) 1.20 (0.96–1.49) 0.111 Hypertension (treated or measured) 1.16 (0.93–1.46) 0.184 SBP (per 10 mm Hg) 1.04 (0.99–1.10) 0.110 Pulse pressure (per 10 mm Hg) 1.02 (0.95–1.10) 0.590 eGFR (per 10 mL/min) 0.95 (0.88–1.02) 0.147 Renal insufficiency (eGFR <60 mL/min) 1.16 (0.84–1.61) 0.375 Smoking (former versus never) 0.70 (0.55–0.90) 0.005 Smoking (current versus never) 0.32 (0.22–0.46) <0.001 Physical activity (per 10 METs h/wk) 1.01 (0.98–1.03) 0.635 ABI indicates ankle brachial index; BMI, body mass index; 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; HDL, highdensity lipoprotein; MET, metabolic equivalent of task; OR, odds ratio; and SBP, systolic blood pressure. ..

    Filtration:

    Article Title: Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population
    Article Snippet: .. Association Between Risk Factors and High Ankle Brachial Index in Patients With An Ankle Brachial Index ≥0.9 Determinant (Predictor) of the Model OR (95% CI) for Having High ABI P Value Age (per 10 y) 1.26 (1.15–1.39) <0.001 Sex (male) 3.00 (2.20–4.09) <0.001 Diabetes mellitus (type 1 or 2) 1.54 (1.21–1.98) <0.001 BMI (per 1 kg/m2) 1.04 (1.01–1.06) 0.004 Non-HDL cholesterol (per 1 mmol/L) 0.89 (0.82–0.98) 0.014 History of hypertension (treated) 1.20 (0.96–1.49) 0.111 Hypertension (treated or measured) 1.16 (0.93–1.46) 0.184 SBP (per 10 mm Hg) 1.04 (0.99–1.10) 0.110 Pulse pressure (per 10 mm Hg) 1.02 (0.95–1.10) 0.590 eGFR (per 10 mL/min) 0.95 (0.88–1.02) 0.147 Renal insufficiency (eGFR <60 mL/min) 1.16 (0.84–1.61) 0.375 Smoking (former versus never) 0.70 (0.55–0.90) 0.005 Smoking (current versus never) 0.32 (0.22–0.46) <0.001 Physical activity (per 10 METs h/wk) 1.01 (0.98–1.03) 0.635 ABI indicates ankle brachial index; BMI, body mass index; 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; HDL, highdensity lipoprotein; MET, metabolic equivalent of task; OR, odds ratio; and SBP, systolic blood pressure. ..



    Similar Products

    non hdl cholesterol levels  (Roche)
    86
    Roche non hdl cholesterol levels
    Non Hdl Cholesterol Levels, supplied by Roche, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/nct03228459-25-0-9
    Average 86 stars, based on 1 article reviews
    non hdl cholesterol levels - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    non hdl cholesterol  (Thermo Fisher)
    97
    Thermo Fisher non hdl cholesterol
    Summary of included studies.
    Non Hdl Cholesterol, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/Cholesterol/pmc12914095-0-100-131
    Average 97 stars, based on 1 article reviews
    non hdl cholesterol - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    non-hdl cholesterol  (Stanbio Inc)
    90
    Stanbio Inc non-hdl cholesterol
    Summary of included studies.
    Non Hdl Cholesterol, supplied by Stanbio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/non+hdl+cholesterol/pm39818839-94-6-8
    Average 90 stars, based on 1 article reviews
    non-hdl cholesterol - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    non-high-density lipoprotein cholesterol (non-hdl-c) to highdensity lipoprotein cholesterol (hdl-c) ratio (nhhr)  (Anhui Medical University)
    90
    Anhui Medical University non-high-density lipoprotein cholesterol (non-hdl-c) to highdensity lipoprotein cholesterol (hdl-c) ratio (nhhr)
    Summary of included studies.
    Non High Density Lipoprotein Cholesterol (Non Hdl C) To Highdensity Lipoprotein Cholesterol (Hdl C) Ratio (Nhhr), supplied by Anhui Medical University, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/high+density+lipoprotein+cholesterol/pm39227001-29-1-43
    Average 90 stars, based on 1 article reviews
    non-high-density lipoprotein cholesterol (non-hdl-c) to highdensity lipoprotein cholesterol (hdl-c) ratio (nhhr) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    non-hdl-cholesterol  (Zambon)
    90
    Zambon non-hdl-cholesterol
    Summary of included studies.
    Non Hdl Cholesterol, supplied by Zambon, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/hdl+cholesterol/pm39098034-186-32-28
    Average 90 stars, based on 1 article reviews
    non-hdl-cholesterol - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    total cholesterol, ldl-cholesterol, hdl-cholesterol, triglycerides, non-hdl cholesterol analyses  (LabCorp)
    90
    LabCorp total cholesterol, ldl-cholesterol, hdl-cholesterol, triglycerides, non-hdl cholesterol analyses
    Summary of included studies.
    Total Cholesterol, Ldl Cholesterol, Hdl Cholesterol, Triglycerides, Non Hdl Cholesterol Analyses, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/total+cholesterol++ldl+cholesterol++hdl+cholesterol++triglycerides++non+hdl+cholesterol+analyses/pmc09920461-170-10-4
    Average 90 stars, based on 1 article reviews
    total cholesterol, ldl-cholesterol, hdl-cholesterol, triglycerides, non-hdl cholesterol analyses - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    precipitating non–hdl cholesterol  (FUJIFILM)
    90
    FUJIFILM precipitating non–hdl cholesterol
    Statin treatment decreases total <t> cholesterol </t> without affecting <t> HDL-C </t> in western-diet fed apoE -/- mice.
    Precipitating Non–Hdl Cholesterol, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/hdl+cholesterol/pmc03232231-129-7-9
    Average 90 stars, based on 1 article reviews
    precipitating non–hdl cholesterol - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    total cholesterol, hdl, non-hdl cholesterol concentrations  (accelab GmbH)
    90
    accelab GmbH total cholesterol, hdl, non-hdl cholesterol concentrations
    Analysis of serum <t> cholesterol. </t>
    Total Cholesterol, Hdl, Non Hdl Cholesterol Concentrations, supplied by accelab GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/total+cholesterol++hdl++non+hdl+cholesterol+concentrations/pmc05745665-71-4-11
    Average 90 stars, based on 1 article reviews
    total cholesterol, hdl, non-hdl cholesterol concentrations - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    non-high density lipoprotein cholesterol (non-hdl-c)  (Pfizer Inc)
    90
    Pfizer Inc non-high density lipoprotein cholesterol (non-hdl-c)
    Analysis of serum <t> cholesterol. </t>
    Non High Density Lipoprotein Cholesterol (Non Hdl C), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/non+high+density+lipoprotein+cholesterol++non+hdl+c+/pmc09034497-201-15-0
    Average 90 stars, based on 1 article reviews
    non-high density lipoprotein cholesterol (non-hdl-c) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    non esterified fatty acid nefa levels  (Randox)
    96
    Randox non esterified fatty acid nefa levels
    Analysis of serum <t> cholesterol. </t>
    Non Esterified Fatty Acid Nefa Levels, supplied by Randox, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/non+hdl+cholesterol/HDL-CHOLESTEROL/pm32942017-58-8-23
    Average 96 stars, based on 1 article reviews
    non esterified fatty acid nefa levels - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Journal: International Journal of Cardiology. Cardiovascular Risk and Prevention

    Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis

    doi: 10.1016/j.ijcrp.2026.200590

    Figure Lengend Snippet: Summary of included studies.

    Article Snippet: Clavijoa, 2023 , RCT, Double-blind , USA , 6 months , Evolocumab 420 mg SC q4w , placebo , 35 , 35 , 70 , Patients aged 40–85 years with a diagnosis of atherosclerotic cardiovascular disease and PAD (Rutherford class I-VI), confirmed by an ankle-brachial index (ABI) ≤0.9 at rest or ≤0.8 after exercise, angiography, duplex ultrasound, or a history of lower extremity surgical or endovascular revascularization. Patients had to be at least one month from their most recent intervention, stable on maximal tolerated lipid-lowering therapy for at least four weeks, and have a fasting LDL cholesterol ≥55 mg/dL or non-HDL cholesterol ≥80 mg/dL. , MWT at 6 months , After six months, Evolocumab significantly improved MWT, FMD, Carotid IMT, and plasma MRP-14 levels. In contrast, changes in pain-free walking time, ABI, TBI, transcutaneous oxygen pressure, oxLDL, and sCD36 were not statistically significant..

    Techniques: Control, Biomarker Discovery, Clinical Proteomics, Activation Assay

    Statin treatment decreases total cholesterol without affecting HDL-C in western-diet fed apoE -/- mice.

    Journal: PLoS ONE

    Article Title: Statins Promote the Regression of Atherosclerosis via Activation of the CCR7-Dependent Emigration Pathway in Macrophages

    doi: 10.1371/journal.pone.0028534

    Figure Lengend Snippet: Statin treatment decreases total cholesterol without affecting HDL-C in western-diet fed apoE -/- mice.

    Article Snippet: Plasma HDL cholesterol was determined by precipitating non–HDL cholesterol (Wako Diagnostic) and then assaying the remaining HDL cholesterol by means of the Infinity Total Cholesterol Reagent.

    Techniques: Western Blot

    Analysis of serum cholesterol.

    Journal: Evidence-based Complementary and Alternative Medicine : eCAM

    Article Title: The Hypocholesterolemic Effects of Eryngium carlinae F. Delaroche Are Mediated by the Involvement of the Intestinal Transporters ABCG5 and ABCG8

    doi: 10.1155/2017/3176232

    Figure Lengend Snippet: Analysis of serum cholesterol.

    Article Snippet: We reported total cholesterol, HDL, and non-HDL cholesterol concentrations (Enzymatic Methods, Accelab, Mexico).

    Techniques: Concentration Assay